Chengjiang Wei

Chengjiang Wei

Auto-generated profile, based on publicly available information

Chengjiang Wei

Neurofibromatosis Type 1 Center and Laboratory for Neurofibromatosis Type 1 Research Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DWDun Wang
Dun Wang
LGLingling Ge
Lingling Ge
ZGZizhen Guo
Zizhen Guo
YLYuehua Li
Yuehua Li
BZBeiyao Zhu
Beiyao Zhu
ZWZhi-Chao Wang
Zhi-Chao Wang
Trametinib has been used in neurofibromatosis type 1 (NF1) patients, especially those with unresectable nerve tumors, but no systematic review based on the latest studies has been published. We conducted this meta-analysis to evaluate the effectiveness and safety of trametinib in treating NF1-related nerve tumors. Original articles reporting the efficacy and safety of trametinib in NF1 patents were identified in PubMed, EMBASE, and Web of Science up to 1 June 2022. Using R software and the ‘meta’ package, the objective response rates (ORRs) and disease control rates (DCRs) were calculated to evaluate the efficacy, and the pooled proportion of adverse events (AEs) was calculated. The Grading of Recommendations, Assessment, Development and Evaluation system was used to assess the quality of evidence. Eight studies involving 92 patients were included, which had a very low to moderate quality of evidence. The pooled ORR was 45.3% (95% CI: 28.9–62.1%, I2 = 0%), and the DCR was 99.8% (95% CI: 95.5–100%, I2 = 0%). The most common AEs was paronychia, with a pooled rate of 60.7% (95% CI: 48.8–72.7%, I2 = 0%). Our results indicate the satisfactory ability to stabilize tumor progression but a more limited ability to shrink tumors of trametinib in NF1-related nerve tumors. The safety profile of trametinib is satisfactory.

1 March 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
XCXi-Wei Cui
Xi-Wei Cui
YGYi-Hui Gu
Yi-Hui Gu
CWCheng-Jiang Wei
Cheng-Jiang Wei
YLYue-Hua Li
Yue-Hua Li
ZWZhi-Chao Wang
Zhi-Chao Wang
MAPK/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors (MEKis) have recently achieved surprising success in treating unresectable plexiform neurofibromas (PNFs). However, few studies have investigated the mechanisms of MEKi resistance in patients with PNF. We determined the efficacy of six different MEKis for treating PNFs, explored drug resistance mechanisms, and identified potential combination therapies to overcome resistance. By screening drug efficacy among six MEKis in human NF1-deficient PNF cell lines, TAK-733 was found to reduce PNF cell viability the most. We then cultured the TAK-733‒resistant cells and explored the potential targets for further treatment. Both high-throughput drug screening and RNA sequencing analyses of MEKi-resistant PNF cells identified cyclin-dependent kinase inhibitors as potential agents for PNFs. Dinaciclib, a cyclin-dependent kinase inhibitor, showed synergistic effects on MEKi-resistant cells. Coadministration of dinaciclib and TAK-733 significantly reduced cell viability and inhibited sphere formation and colony formation. Dinaciclib did not affect MEK signaling but decreased the expression of several prosurvival proteins, including survivin and cyclin-dependent kinase 1, to induce apoptosis and inhibit mitosis. TAK-733/dinaciclib combination therapy induced tumor reduction in PNF patient‒derived xenografts mouse models. Therefore, the combination of MEKi and cyclin-dependent kinase inhibitor may be promising for treating inoperable PNFs, especially when drug resistance exists. Our findings provide evidence for future clinical trials with MEKi-resistant patients with PNF.

24 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YLYuehua Li
Yuehua Li
MCManhon Chung
Manhon Chung
RARehanguli Aimaier
Rehanguli Aimaier
CWChengjiang Wei
Chengjiang Wei
WWWei Wang
Wei Wang
ZWZhi-Chao Wang
Zhi-Chao Wang
(1) Background: malignant peripheral nerve sheath tumours (MPNSTs) are aggressive Schwann cell-derived sarcomas with dismal prognoses. Previous studies have shown that nuclear receptor corepressor 2 (NCOR2) plays a vital role in neurodevelopment and in various tumours. However, the impact of NCOR2 on the progression of MPNST remains unclear. (2) Methods: by GEO database, MPNST tissue microarray, and NF1-related tumour tissues and cell lines were used to explore NCOR2 expression level in the MPNSTs. The role and mechanism of NCOR2 in NF1-derived MPNSTs were explored by experiments in vivo and in vitro and by transcriptome high-throughput sequencing. (3) Results: NCOR2 expression is significantly elevated in NF1-derived MPNSTs and is associated with patient 10-year survival time. Knockdown of NCOR2 suppressed NF1-derived MPNST cell proliferation by blocking the cell cycle in the G0/G1 phase. Moreover, decreased NCOR2 expression could down-regulate MAPK signal activity through the BDNF/TrkB pathway. (4) Conclusions: our findings demonstrated that NCOR2 expression is significantly elevated in NF1-derived MPNSTs. NCOR2 knockdown can inhibit NF1-derived MPNST cell proliferation by weakened BDNF/TrkB/ERK signalling. Targeting NF1-derived MPNSTs with TrkB inhibitors, or in combination with ERK inhibitors, may be a novel therapeutic strategy for clinical trials.

8 November 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
LGLingling Ge
Lingling Ge
ZWZhi-Chao Wang
Zhi-Chao Wang
CWCheng-Jiang Wei
Cheng-Jiang Wei
JHJing-Xuan Huang
Jing-Xuan Huang
JLJun Liu
Jun Liu
QLQingfeng Li
Qingfeng Li

11 February 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZWZhi-Chao Wang
Zhi-Chao Wang
JHJingxuan Huang
Jingxuan Huang
JLJun Liu
Jun Liu
YLYuehua Li
Yuehua Li
CWChengjiang Wei
Chengjiang Wei
QLQingfeng Li
Qingfeng Li
Purpose: Plexiform neurofibromas (PN) present a significant clinical challenge, with a notable unmet need for effective and well-tolerated therapies, particularly for the adult population. Patients and Methods: A single-arm, open-label, phase IIa trial of tunlametinib was conducted to assess its efficacy and safety in adults with inoperable, radiologically measurable PN. Patients received tunlametinib at a dose of 9 mg twice daily, following a continuous 21-day cycle regimen. The primary endpoint was the confirmed objective response rate (ORR), and secondary endpoints included disease control rate, duration of response, progression-free survival, and improvements in patient-reported outcomes (PRO) compared with baseline. Exploratory analyses integrating clinical variables and single-cell transcriptomic profiles were performed to explore response heterogeneity. Results: Of 15 adults (10 males and five females; median age, 27 years; range, 18–45), eight patients achieved a confirmed partial response, with an ORR of 53.3% (95% confidence interval, 26.69–78.73) and a median neurofibroma volume reduction of −23.5% (range, 1.6% to −49.1%). Significant improvements in multiple PRO domains were observed, including Patients’ Global Impression of Change and the Plexiform Neurofibromas Quality of Life scale. Regarding safety, all patients experienced at least one treatment-related adverse event, the majority of which were grade 1 or 2. Single-cell RNA sequencing profiling of pretreatment biopsies from one rapid responder and two gradual responders revealed substantial microenvironmental heterogeneity. Conclusions: Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with the prior PN trials, including selumetinib and mirdametinib.

30 March 2026 in Medcomm
Verified
Journal Article
Open access
LGLing‐Ling Ge
Ling‐Ling Ge
YLYue‐Hua Li
Yue‐Hua Li
XYXuan Yu
Xuan Yu
MXMing‐Yan Xing
Ming‐Yan Xing
YGYi‐Hui Gu
Yi‐Hui Gu
QLQingfeng Li
Qingfeng Li
Neurofibromatosis type 1 (NF1) is characterized by the development of benign plexiform neurofibromas (PNFs). In 10%–15% of patients, these tumors undergo malignant transformation into aggressive malignant peripheral nerve sheath tumors (MPNSTs). The underlying mechanisms driving this malignant progression remain poorly understood, hindering the development of effective therapies. To address this gap, we performed single‐cell RNA sequencing on nine PNF and five MPNST samples. Our analysis revealed tumor microenvironment remodeling during malignant progression, marked by a significant increase in immune cells. Within the macrophage compartment, we identified three distinct SPP1 + subpopulations. Among these, the SPP1 + KYNU + subset exhibited pronounced upregulation of genes related to tryptophan metabolism. This metabolically active macrophage population exhibited strong interaction with POSTN + fibroblasts enriched in MPNSTs. Functional experiments found that this crosstalk promotes fibroblast activation and enhances migratory capacity. Furthermore, the metabolic reprogramming of SPP1 + KYNU + macrophages was associated with the establishment of an immunosuppressive microenvironment characterized by T cell dysfunction. Collectively, our findings define a central role for SPP1 + KYNU + macrophages in coordinating both stromal remodeling and immune suppression during MPNST progression. These results not only advance our understanding of NF1‐associated tumorigenesis but also identify tryptophan metabolism as a promising therapeutic target and potential diagnostic biomarker for MPNSTs.